Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RRR: Ranibizumab for Radiation Retinopathy
NCT02222610Phase 2Completed
- Sponsor
- Greater Houston Retina Research Center
- Start
- Sep 2014
- Primary completion
- Mar 2019
- Modality
- Antibody Fragments, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised trial of ranibizumab in radiation retinopathy (RR) (3 arms), sponsored by Greater Houston Retina Research Center. Primary endpoint: Mean Change in Early Treatment Diabetic Retinopathy Study (ETDRS) Visual Acuity at 104 weeks. Started Sep 2014; status: completed.
02
Drugs
ranibizumab
03
Conditions
radiation retinopathy (RR)
Beyond the preview
Go deeper on NCT02222610.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02222610.